Dynamic quotes: Off
|
Company Description (as filed with the SEC)
We are a clinical-stage biotechnology company engaged in the research and development of innovative cancer therapeutics. Our mission is to produce novel drugs with differentiated mechanisms of action that will extend the lives of our patients. These drugs target biological pathways implicated in a wide range of cancers. We employ technologies such as our ArQule Kinase Inhibitor Platform (“AKIPTM”) to design and develop drugs that have the potential to fulfill this mission. Our product candidates and programs span a continuum of research and development ranging from drug discovery to advanced clinical testing. They are based on our understanding of biological processes that lead to the proliferation and metastasis of cancer cells, combined with our ability to generate product candidates possessing certain pre-selected, drug-like properties. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-0.18 |
| Quarterly EPS Est: | -0.11 |
| PEG Ratio: | -.01 |
|
Mean Recommendation: View Summary / View All |
2.33 |
Data is provided by Zacks Investment Research

